In Brief: MGI Pharma
Executive Summary
MGI Pharma: Decision Network Committee of the National Cancer Institute has voted in favor of funding and conducting human clinical trials of MGI 114, the lead analog among the company's acylfulvenes, MGI Pharma announces July 25. A clinical trials agreement between NCI and the company has not yet been completed. MGI Pharma states that the NCI trial would complement ongoing Phase I research of MGI 114 in cancer patients, which the company initiated in December...